Intravaginal ring protects against HIV and herpes

The ring, that will soon undergo clinical trials in women, delivers controlled doses of tenofovir over 90 days, which protects against both HIV and herpes, along with the contraceptive, levonorgestrel.

According to the researchers from Northwestern University, the ring presented a particular design challenge because while tenofovir is water soluble, levonorgestrel is not.

The daily dose of both drugs is also different.

This meant it had to be designed as three separate polyurethane rings, with the middle ring keeping the two drugs